BOLD Boundless Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1782303 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY10.1%
TTM EPS YoY7.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-64.6%
ROA-47.8%
ROIC (approx.)-76.5%
Asset turnover—
Leverage & solvency
Liabilities / assets2.9%
Debt / equity0.00x
Current ratio33.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio1.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $44.84M | $55.27M | $42.64M |
| SG&A expense | $18.71M | $18.00M | $12.16M |
| Operating income | -$63.55M | -$73.27M | -$54.80M |
| Income tax | $0 | $0 | — |
| Net income | -$58.20M | -$65.36M | -$49.43M |
| EBITDA | -$62.30M | -$72.18M | -$53.84M |
| EPS (basic) | -2.60 | -3.85 | -40.65 |
| EPS (diluted) | -2.60 | -3.85 | -40.65 |
| Weighted avg. shares (diluted) | 22.36M | 16.98M | 1.22M |
| Balance sheet | |||
| Cash & equivalents | $17.87M | $27.15M | $24.27M |
| Short-term investments | $89.71M | $125.53M | $97.05M |
| Current assets | $109.61M | $154.39M | $124.20M |
| PP&E, net | $3.22M | $4.32M | $2.57M |
| Total assets | $157.06M | $206.41M | $129.89M |
| Current liabilities | $12.54M | $8.13M | $9.36M |
| Total liabilities | $58.41M | $55.77M | $9.36M |
| Shareholders' equity | $98.65M | $150.64M | -$127.08M |
| Shares outstanding | 22.41M | 22.30M | 1,248 |
| Cash flow statement | |||
| Operating cash flow | -$46.66M | -$60.84M | -$46.85M |
| Capital expenditure | $546,000 | $2.54M | $633,000 |
| Free cash flow | -$47.21M | -$63.38M | -$47.49M |
| Investing cash flow | $37.80M | -$26.10M | -$38.26M |
| Financing cash flow | $141,000 | $89.82M | $97.90M |
| Depreciation & amortization | $1.25M | $1.09M | $957,000 |
| Stock-based compensation | $6.12M | $7.52M | $3.34M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.